JP6452954B2 - 癌転移抑制剤 - Google Patents

癌転移抑制剤 Download PDF

Info

Publication number
JP6452954B2
JP6452954B2 JP2014102285A JP2014102285A JP6452954B2 JP 6452954 B2 JP6452954 B2 JP 6452954B2 JP 2014102285 A JP2014102285 A JP 2014102285A JP 2014102285 A JP2014102285 A JP 2014102285A JP 6452954 B2 JP6452954 B2 JP 6452954B2
Authority
JP
Japan
Prior art keywords
cancer
mirtazapine
cells
expression
lin7c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014102285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014240383A5 (enExample
JP2014240383A (ja
Inventor
秀樹 丹沢
秀樹 丹沢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University
Original Assignee
Chiba University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University filed Critical Chiba University
Priority to JP2014102285A priority Critical patent/JP6452954B2/ja
Publication of JP2014240383A publication Critical patent/JP2014240383A/ja
Publication of JP2014240383A5 publication Critical patent/JP2014240383A5/ja
Application granted granted Critical
Publication of JP6452954B2 publication Critical patent/JP6452954B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014102285A 2013-05-16 2014-05-16 癌転移抑制剤 Expired - Fee Related JP6452954B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014102285A JP6452954B2 (ja) 2013-05-16 2014-05-16 癌転移抑制剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013104409 2013-05-16
JP2013104409 2013-05-16
JP2014102285A JP6452954B2 (ja) 2013-05-16 2014-05-16 癌転移抑制剤

Publications (3)

Publication Number Publication Date
JP2014240383A JP2014240383A (ja) 2014-12-25
JP2014240383A5 JP2014240383A5 (enExample) 2017-07-06
JP6452954B2 true JP6452954B2 (ja) 2019-01-16

Family

ID=52139848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014102285A Expired - Fee Related JP6452954B2 (ja) 2013-05-16 2014-05-16 癌転移抑制剤

Country Status (1)

Country Link
JP (1) JP6452954B2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6915865B2 (ja) * 2017-10-03 2021-08-04 学校法人 愛知医科大学 Ｎｏ産生抑制剤及び固形腫瘍に対する転移・浸潤抑制剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain

Also Published As

Publication number Publication date
JP2014240383A (ja) 2014-12-25

Similar Documents

Publication Publication Date Title
Mo et al. Human ABCG2: structure, function, and its role in multidrug resistance
EP1426054B1 (en) Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US20140364460A1 (en) USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
JP7719135B2 (ja) 微小残存がんを治療する方法
US8703736B2 (en) Therapeutic target for pancreatic cancer cells
KR102338568B1 (ko) 퀴나졸린 유도체
US9255270B2 (en) Methods used in sensitizing invasive glioblastoma to therapeutic treatment
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Zhou et al. RETRACTED ARTICLE: PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation
Zheng et al. The in vitro and in vivo study of a pyrazole derivative, J-1063, as a novel anti-liver fibrosis agent: Synthesis, biological evaluation, and mechanistic analysis
US20230366033A1 (en) Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
US20210186982A1 (en) Methods and compositions for treating melanoma
WO2023044501A2 (en) Methods for treating a subtype of colorectal cancer
US20200155526A1 (en) Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
US20210205349A1 (en) Inhibition of ngly1 for the treatment of cancer
JP2014240383A (ja) 癌転移抑制剤
WO2025087879A2 (en) Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2013166366A1 (en) Cul4b as predictive biomarker for cancer treatment
WO2017091952A1 (zh) Akt2在诊断和治疗肿瘤中的用途
Wang et al. A modified nucleoside O6-methyl-2′-deoxyguanosine-5′-triphosphate exhibits anti-glioblastoma activity in a caspase-independent manner
JP7510144B2 (ja) 抗癌剤及びその使用
EP4361136A1 (en) Compound for the treatment of glioblastoma
US20090285836A1 (en) Use of salinosporamide a to inhibit metastasis
KR101900278B1 (ko) Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법
US9872857B2 (en) Methods of using propentofylline to treat glioma and glioblastoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181212

R150 Certificate of patent or registration of utility model

Ref document number: 6452954

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees